ZOMEDICA CORP (ZOM)
CA98980M1095 - Common Stock
Taking everything into account, ZOM scores 4 out of 10 in our fundamental rating. ZOM was compared to 187 industry peers in the Health Care Equipment & Supplies industry. While ZOM has a great health rating, there are worries on its profitability. ZOM is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ZOM had negative earnings in the past year.
ZOM had a negative operating cash flow in the past year.
ZOM had negative earnings in each of the past 5 years.
ZOM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -29.05%, ZOM perfoms like the industry average, outperforming 44.62% of the companies in the same industry.
ZOM's Return On Equity of -30.66% is in line compared to the rest of the industry. ZOM outperforms 56.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.05% | ||
| ROE | -30.66% | ||
| ROIC | N/A |
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ZOM's Gross Margin of 69.64% is amongst the best of the industry. ZOM outperforms 80.65% of its industry peers.
ZOM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZOM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ZOM has about the same amount of shares outstanding.
Compared to 5 years ago, ZOM has more shares outstanding
ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 5.81 indicates that ZOM is not in any danger for bankruptcy at the moment.
ZOM's Altman-Z score of 5.81 is amongst the best of the industry. ZOM outperforms 81.18% of its industry peers.
ZOM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.81 |
ROIC/WACCN/A
WACC9.18%
2.3 Liquidity
A Current Ratio of 10.82 indicates that ZOM has no problem at all paying its short term obligations.
ZOM has a Current ratio of 10.82. This is amongst the best in the industry. ZOM outperforms 94.09% of its industry peers.
A Quick Ratio of 10.15 indicates that ZOM has no problem at all paying its short term obligations.
ZOM's Quick ratio of 10.15 is amongst the best of the industry. ZOM outperforms 94.09% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.82 | ||
| Quick Ratio | 10.15 |
3. Growth
3.1 Past
The earnings per share for ZOM have decreased strongly by -57.89% in the last year.
Looking at the last year, ZOM shows a quite strong growth in Revenue. The Revenue has grown by 11.33% in the last year.
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
3.2 Future
ZOM is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.13% yearly.
ZOM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.91% yearly.
EPS Next Y56.09%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y-7.13%
Revenue Next Year37.23%
Revenue Next 2Y25.58%
Revenue Next 3Y25.89%
Revenue Next 5Y23.91%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ZOM. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ZOM's earnings are expected to grow with 25.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y25.99%
5. Dividend
5.1 Amount
ZOM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZOMEDICA CORP
NYSEARCA:ZOM (1/3/2025, 8:12:07 PM)
After market: 0.1471 +0 (+0.14%)0.1469
+0.01 (+6.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners8.62%
Inst Owner Change-3.85%
Ins Owners0.64%
Ins Owner Change2.02%
Market Cap143.95M
Analysts80
Price Target0.26 (76.99%)
Short Float %4.48%
Short Ratio7.2
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.83%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)-20.3%
Revenue beat(4)1
Avg Revenue beat(4)-17.04%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)3.78%
Revenue beat(8)1
Avg Revenue beat(8)-16.36%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-43.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-8.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.39 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.71 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.03
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.03
BVpS0.21
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.05% | ||
| ROE | -30.66% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.64% | ||
| FCFM | N/A |
ROA(3y)-8.76%
ROA(5y)-104.96%
ROE(3y)-9.18%
ROE(5y)-199.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 86.87% | ||
| Cap/Sales | 25.37% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.82 | ||
| Quick Ratio | 10.15 | ||
| Altman-Z | 5.81 |
F-Score4
WACC9.18%
ROIC/WACCN/A
Cap/Depr(3y)120.38%
Cap/Depr(5y)90.3%
Cap/Sales(3y)29.66%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-57.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-900%
EPS Next Y56.09%
EPS Next 2Y41.42%
EPS Next 3Y25.99%
EPS Next 5Y-7.13%
Revenue 1Y (TTM)11.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.29%
Revenue Next Year37.23%
Revenue Next 2Y25.58%
Revenue Next 3Y25.89%
Revenue Next 5Y23.91%
EBIT growth 1Y-50.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-88.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70%
OCF growth 3YN/A
OCF growth 5YN/A